Evaluation of musculoskeletal adverse effects in patients on systemic isotretinoin treatment: A cross-sectional study       
Yazarlar (3)
Emine Müge Acar
T.C. Sağlık Bakanlığı, Türkiye
Senem Şaş
Erciyes University, Faculty Of Medicine, Türkiye
Prof. Dr. Fatmanur Aybala KOÇAK Kırşehir Ahi Evran Üniversitesi, Türkiye
Makale Türü Açık Erişim Özgün Makale
Makale Alt Türü SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale
Dergi Adı Archives of Rheumatology
Dergi ISSN 2618-6500 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Dergi Grubu Q4
Makale Dili İngilizce
Basım Tarihi 01-2022
Cilt No 37
Sayı 2
Sayfalar 223 / 229
DOI Numarası 10.46497/ArchRheumatol.2022.8645
Makale Linki file:///C:/Users/fayba/Downloads/2000-1-1-952-953-eng.pdf
Özet
Objectives: This study aims to investigate the frequency of musculoskeletal adverse effects in acne vulgaris patients receiving systemic isotretinoin
treatment.
Patients and methods: Between January 2016 and December 2017, a total of 200 severe acne patients (22 males, 178 females;
mean age: 21.8±0.4 years; range, 15 to 53 years) who were on isotretinoin treatment were retrospectively analyzed. Data including age, sex,
body mass index (BMI), duration of disease, diagnosis, and comorbidities were recorded. Back pain severity was evaluated with the Visual
Analog Scale (VAS).
Results: The treatment period was mean 8.5±0.1 (range, 6 to 12) months. The dose of isotretinoin was mean 0.6±0.1 (range, 0.5 and 1) mg/kg.
Musculoskeletal side effects were seen in 99 (49.5%) patients. Back pain was reported during the treatment period in 78 (78.7%) patients. The
diagnosis was mechanical back pain in 31 (39.7%) and inflammatory back pain in 47 (60.3%) patients. The moderate-severe back pain group
received higher cumulative isotretinoin doses than the mild back pain group (p=0.003). The BMI values did not show a significant difference
between the patients with and without back pain (p=0.55). There was no significant correlation between the BMI and VAS scores (p=0.06). The
VAS scores were found to be correlated with age (p=0.04). Sacroiliitis was diagnosed in four (4%) patients. One (1%) patient was diagnosed
with enthesitis. Creatine kinase elevation was reported in 18 (18.1%) patients, while three (3%) patients described myalgia of mild severity.
Conclusion: Low back pain is one of the most common musculoskeletal side effects of isotretinoin treatment that usually resolves with dose
reduction. The cumulative dose of isotretinoin does not seem to play a role in the development of back pain, but can determine pain severity. Pain
severity is directly correlated with the increasing age. Evaluation of the patients for musculoskeletal side effects during isotretinoin use is important
in clinical practice, as it is a common occurrence.
Anahtar Kelimeler
Acne | hyperostosis | inflammatory back pain | sacroiliitis | spondyloarthropathy | systemic isotretinoin